Blog

SK pharmteco’s subsidiary Yposkesi launches AAVelocity, a plug-and-play Adeno-Associated Virus (AAV) platform

Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use

On-Demand Webinar, Unlocking allogeneic cell therapy success: downstream strategies for commercialization

Allogeneic cell therapies are on the cusp of a transformative breakthrough, fueled by promising clinical data and compelling long-term trends. As the field advances towards large-scale commercialization, a critical focal point emerges: the optimization of downstream processes.

Scaling Up Gene Therapy Manufacturing: Strategies to Overcome Capacity Challenges

As vector-delivered advanced therapies inch towards commercialization, a significant bottleneck has emerged: experienced manufacturing capacity.

Plasmid Power: Navigating Challenges with Precision and Quality in Advanced Therapy Development

When developing advanced therapies, the significance of plasmids cannot be overstated. These genetic building blocks form the backbone of cell and gene therapies

The Future of Advanced Therapy Delivery: Insights from Industry Experts

The realm of advanced therapies is on the cusp of an evolution, driven by the need to overcome the challenges that come with the success of adeno-associated vector (AAV)-based therapies.

Navigating Preclinical Manufacturing: Paving the Path to Clinical Success

Cell and gene therapy has tremendous potential, yet the journey from discovery to clinical success is a multifaceted endeavor.

Scaling Allogeneic Cell Therapy Manufacturing

A contract development and manufacturing organization (CDMO) is an outsourcing agency for pharmaceutical and life sciences industries specializing in the precise and delicate process of creating and bulk-producing life-changing and lifesaving drugs.

Scaling Up Gene Therapy Manufacturing

Scaling up gene therapy manufacturing involves increasing production capacity while maintaining the quality and consistency of the product.

Lentiviral Vector Manufacturing and Distribution

Gene and cell therapy medicines, in particular those delivered via lentiviruses, are poised to be the future of disease treatment.

What Should Companies Look For When Selecting a CDMO For Process Development (PD)

The best PD offerings are integrated services over the entire therapeutic development cycle--from initial development to commercialization.

The Importance of High-Quality Precision Plasmids for Cell and Gene Therapies

De-Risking C&GT Therapies Early In Process Development

De-risking C> therapies early in process development is critical to ensuring patient safety and maximizing the therapy's potential benefits.

CAR T Testing Strategies

CAR T-cell therapy is an innovative approach to treating cancer that involves engineering a patient's T cells to recognize and attack cancer cells. However, developing a CAR T testing strategy can be a complex process that requires careful consideration of many factors.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Blog

SK pharmteco’s subsidiary Yposkesi launches AAVelocity, a plug-and-play Adeno-Associated Virus (AAV) platform

On-Demand Webinar, Unlocking allogeneic cell therapy success: downstream strategies for commercialization

Scaling Up Gene Therapy Manufacturing: Strategies to Overcome Capacity Challenges

Plasmid Power: Navigating Challenges with Precision and Quality in Advanced Therapy Development

The Future of Advanced Therapy Delivery: Insights from Industry Experts

Navigating Preclinical Manufacturing: Paving the Path to Clinical Success

Scaling Allogeneic Cell Therapy Manufacturing

Scaling Up Gene Therapy Manufacturing

Lentiviral Vector Manufacturing and Distribution

What Should Companies Look For When Selecting a CDMO For Process Development (PD)

The Importance of High-Quality Precision Plasmids for Cell and Gene Therapies

De-Risking C&GT Therapies Early In Process Development

CAR T Testing Strategies

Plasmid DNA Manufacturing for Cell and Gene Therapies

What is Cell Therapy Manufacturing

First-time Right Approach to Advanced Therapy Process Development

Cell Banking with CDMOs

What is Viral Vector Manufacturing

Blog

Contact us to discuss how CBM’s integrated capabilities can support your program

Viral Vector Manufacturing

Cell Therapy Manufacturing

Our Experienced Team